Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $77.00 price target on the biotechnology company’s stock. CAPR has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating and set […]
More Stories
Minerva Academy: Release Date, Plot, Cast, Trailer, and More
Netflix’s latest Italian drama Minerva Academy is currently streaming online on the popular streaming network Netflix. Its original title is...
8 Best Commercial Skylight Companies for US Projects (2026)
Getting commercial daylighting wrong is expensive in a way residential work rarely is. A leaking curb on a house is...
Is Sweet Magnolias Season 6 Renewed? Latest News and Review
Netflix’s romantic drama Sweet Magnolias has finally come to an end. In September 2026, Deadline officially announced that one of...
The Inbetweeners 3: Release Date, Cast, Trailer, and Updates
The Inbetweeners 3 is finally coming back on the popular streaming Network, Netflix. The original four stars of the series,...
7 Essential Components of a Modern Corporate Training Tech Stack
What the seven components need to accomplish Your LMS isn’t obsolete. It may simply need to play one part in...
Climate-ready workplaces in 2026: managing heat, flooding, ice and severe weather
Irish and British workplaces are facing severe weather with increasing frequencies, from heatwares and flash flooding to ice underfoot. Preparing...